Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Judy Chang

Showing results (71-80 of 77) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 77 results.
AIDS (London, England)|September 29, 2021
Neurotoxicity with high-dose disulfiram and vorinostat used for HIV latency reversalJames H McMahon, Vanessa A Evans, Jillian S Y Lau, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 9, 2022
Antiretroviral Initiation at ≥800 CD4+ Cells/mm3 Associated With Lower Human Immunodeficiency Virus Reservoir SizeThomas A Rasmussen, Sunil K Ahuja, Locadiah Kuwanda, et al.
Molecular Therapy. Nucleic Acids|January 6, 2016
TALENs Facilitate Single-step Seamless SDF Correction of F508del CFTR in Airway Epithelial Submucosal Gland Cell-derived CF-iPSCsShingo Suzuki, R Geoffrey Sargent, Beate Illek, et al.
Cell Reports. Medicine|October 5, 2022
Memory CD4<sup>+</sup> T cells that co-express PD1 and CTLA4 have reduced response to activating stimuli facilitating HIV latencyThomas A Rasmussen, Jennifer M Zerbato, Ajantha Rhodes, et al.
Journal of Virus Eradication|November 30, 2020
A randomized trial of vorinostat with treatment interruption after initiating antiretroviral therapy during acute HIV-1 infectionEugène D M B Kroon, Jintanat Ananworanich, Amélie Pagliuzza, et al.
Plos Medicine|June 8, 2021
Ending AIDS as a public health threat by 2030: Time to reset targets for 2025Paul R De Lay, Adèle Benzaken, Quarraisha Abdool Karim, et al.
Ebiomedicine|February 28, 2021
A clinical trial of non-invasive imaging with an anti-HIV antibody labelled with copper-64 in people living with HIV and uninfected controlsJames H McMahon, Jennifer M Zerbato, Jillian S Y Lau, et al.
Pageof 8

Showing results (71-80 of 77) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 77 results.
AIDS (London, England)|September 29, 2021
Neurotoxicity with high-dose disulfiram and vorinostat used for HIV latency reversalJames H McMahon, Vanessa A Evans, Jillian S Y Lau, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 9, 2022
Antiretroviral Initiation at ≥800 CD4+ Cells/mm3 Associated With Lower Human Immunodeficiency Virus Reservoir SizeThomas A Rasmussen, Sunil K Ahuja, Locadiah Kuwanda, et al.
Molecular Therapy. Nucleic Acids|January 6, 2016
TALENs Facilitate Single-step Seamless SDF Correction of F508del CFTR in Airway Epithelial Submucosal Gland Cell-derived CF-iPSCsShingo Suzuki, R Geoffrey Sargent, Beate Illek, et al.
Cell Reports. Medicine|October 5, 2022
Memory CD4<sup>+</sup> T cells that co-express PD1 and CTLA4 have reduced response to activating stimuli facilitating HIV latencyThomas A Rasmussen, Jennifer M Zerbato, Ajantha Rhodes, et al.
Journal of Virus Eradication|November 30, 2020
A randomized trial of vorinostat with treatment interruption after initiating antiretroviral therapy during acute HIV-1 infectionEugène D M B Kroon, Jintanat Ananworanich, Amélie Pagliuzza, et al.
Plos Medicine|June 8, 2021
Ending AIDS as a public health threat by 2030: Time to reset targets for 2025Paul R De Lay, Adèle Benzaken, Quarraisha Abdool Karim, et al.
Ebiomedicine|February 28, 2021
A clinical trial of non-invasive imaging with an anti-HIV antibody labelled with copper-64 in people living with HIV and uninfected controlsJames H McMahon, Jennifer M Zerbato, Jillian S Y Lau, et al.
Pageof 8